Mesenchymal stem cell (MSC)-based therapy involving both autologous and allogeneic MSCs shows great promise in treating several conditions. MSCs promote wound healing, and can differentiate into multiple cell lineages, including keratinocytes. Therefore, MSCs can be used for the treatment of congenital or acquired skin defects. Because of their immunomodulatory properties, MSCs may be useful for the treatment of inflammatory and autoimmune skin diseases. In particular, MSCs might be effective for the treatment of large vitiligo lesions as immunosuppressant or cultured grafts. MSCs can also be a novel cell source for regenerating hair in the treatment of scarring alopecia and androgenic alopecia. MSCs might also be an effective treatment for alopecia areata, which is associated with autoimmunity. Stem cell therapies with topical administration of MSCs and bone marrow transplantation were shown to alleviate recessive dystrophic epidermolysis bullosa in both animal models and human subjects. In addition to cell transplantation, the mobilization of endogenous MSCs has been attempted for skin regeneration. Overall, this review highlights the great potential of MSCs for the treatment of skin diseases in the near future.
Citation: Toshio Hasegawa, Shigaku Ikeda. Mesenchymal Stem Cells for the Treatment of Skin Diseases[J]. AIMS Cell and Tissue Engineering, 2017, 1(2): 104-117. doi: 10.3934/celltissue.2017.2.104
Related Papers:
[1]
Jiangbo Hao, Lirong Huang, Maoxing Liu, Yangjun Ma .
Analysis of the COVID-19 model with self-protection and isolation measures affected by the environment. Mathematical Biosciences and Engineering, 2024, 21(4): 4835-4852.
doi: 10.3934/mbe.2024213
[2]
Abdelheq Mezouaghi, Salih Djillali, Anwar Zeb, Kottakkaran Sooppy Nisar .
Global proprieties of a delayed epidemic model with partial susceptible protection. Mathematical Biosciences and Engineering, 2022, 19(1): 209-224.
doi: 10.3934/mbe.2022011
[3]
Fang Wang, Lianying Cao, Xiaoji Song .
Mathematical modeling of mutated COVID-19 transmission with quarantine, isolation and vaccination. Mathematical Biosciences and Engineering, 2022, 19(8): 8035-8056.
doi: 10.3934/mbe.2022376
[4]
Yujie Sheng, Jing-An Cui, Songbai Guo .
The modeling and analysis of the COVID-19 pandemic with vaccination and isolation: a case study of Italy. Mathematical Biosciences and Engineering, 2023, 20(3): 5966-5992.
doi: 10.3934/mbe.2023258
[5]
Hamdy M. Youssef, Najat A. Alghamdi, Magdy A. Ezzat, Alaa A. El-Bary, Ahmed M. Shawky .
A new dynamical modeling SEIR with global analysis applied to the real data of spreading COVID-19 in Saudi Arabia. Mathematical Biosciences and Engineering, 2020, 17(6): 7018-7044.
doi: 10.3934/mbe.2020362
[6]
Yong Zhou, Minrui Guo .
Isolation in the control of epidemic. Mathematical Biosciences and Engineering, 2022, 19(11): 10846-10863.
doi: 10.3934/mbe.2022507
[7]
Xinmiao Rong, Liu Yang, Huidi Chu, Meng Fan .
Effect of delay in diagnosis on transmission of COVID-19. Mathematical Biosciences and Engineering, 2020, 17(3): 2725-2740.
doi: 10.3934/mbe.2020149
[8]
Jiying Ma, Wei Lin .
Dynamics of a stochastic COVID-19 epidemic model considering asymptomatic and isolated infected individuals. Mathematical Biosciences and Engineering, 2022, 19(5): 5169-5189.
doi: 10.3934/mbe.2022242
[9]
Li-Xiang Feng, Shuang-Lin Jing, Shi-Ke Hu, De-Fen Wang, Hai-Feng Huo .
Modelling the effects of media coverage and quarantine on the COVID-19 infections in the UK. Mathematical Biosciences and Engineering, 2020, 17(4): 3618-3636.
doi: 10.3934/mbe.2020204
[10]
Fernando Saldaña, Hugo Flores-Arguedas, José Ariel Camacho-Gutiérrez, Ignacio Barradas .
Modeling the transmission dynamics and the impact of the control interventions for the COVID-19 epidemic outbreak. Mathematical Biosciences and Engineering, 2020, 17(4): 4165-4183.
doi: 10.3934/mbe.2020231
Abstract
Mesenchymal stem cell (MSC)-based therapy involving both autologous and allogeneic MSCs shows great promise in treating several conditions. MSCs promote wound healing, and can differentiate into multiple cell lineages, including keratinocytes. Therefore, MSCs can be used for the treatment of congenital or acquired skin defects. Because of their immunomodulatory properties, MSCs may be useful for the treatment of inflammatory and autoimmune skin diseases. In particular, MSCs might be effective for the treatment of large vitiligo lesions as immunosuppressant or cultured grafts. MSCs can also be a novel cell source for regenerating hair in the treatment of scarring alopecia and androgenic alopecia. MSCs might also be an effective treatment for alopecia areata, which is associated with autoimmunity. Stem cell therapies with topical administration of MSCs and bone marrow transplantation were shown to alleviate recessive dystrophic epidermolysis bullosa in both animal models and human subjects. In addition to cell transplantation, the mobilization of endogenous MSCs has been attempted for skin regeneration. Overall, this review highlights the great potential of MSCs for the treatment of skin diseases in the near future.
1.
Introduction
In December 2019, COVID-19 (Corona Virus Disease 2019) named by the World Health Organization was first diagnosed in China. Until now, the COVID-19 in China is basically under control, but there are still many infections around the world. WHO Director-General Tedros Adhanom Ghebreyesus said on March 11, 2020 that COVID-19 has pandemic characteristics. The disease has now spread globally, including cases confirmed in 220 Countries. According to the latest real-time statistics of the WHO, as of November 26, 2020, there have been a total of 60,074,174 confirmed cases of COVID-19, and a total of 1,416,292 deaths [1]. The most infected countries distributed in descending order of infected cases are United States of America, India, Brazil, Russian Federation, France, Spain, The United Kingdom, Italy, etc. To defeat the epidemic, scientists in different fields have contributed to COVID-19 [2,3,4,5,6,7,8,9].
The disease dynamic models continue to play an important role in predicting the development trend of infectious disease epidemics, scientific prevention and control guidance, and provide important data basis and theoretical support for the decision-making of public health managers and the implementation of efficient intervention measures. The SIR model proposed by Kermack and McKendrick [10] has been widely used to study infectious diseases. Differential equations and dynamical system methods are widely used to study the origin, evolution and spread of various diseases. In particular, the dynamic model has achieved fruitful results in rabies [11,12], malaria [13], cholera [14], brucellosis [15] and HFMD(Hand, foot and mouth disease) [16]. There also has been a large amount of literatures using dynamic models to analyze the spread and outbreak of COVID-19 [2,3,8,17,18,19,20,21,22,23,24]. Jiao et al. [2] studied an SEIR with infectivity in incubation period and homestead-isolation on the susceptible. Their research results indicate that governments should strictly implement the isolation system to make every effort to curb the spread of disease during the epidemic. Li et al. [3] revealed the effects of city lock-down date on the final scale of cases and analyzed the impact of the city lock-down date on the final scale of cases by studied the transmission of COVID-19 in Shanxi Province. He et al. [8] proposed an SEIR model for the COVID-19 which is built according to some related factors, such as hospital, quarantine and external input. The particle swarm optimization (PSO) algorithm is applied to estimate the parameters of the system. They show that, for the given parameters, if there exists seasonality and stochastic infection, the system can generate chaos. Bouchnita [17] et al use a multi-scale model of COVID-19 transmission dynamics to quantify the effects of restricting population movement and wearing face masks on disease spread in Morocco. Bardina [19] and Zhang et al. [20] using a stochastic infectious disease model to study COVID-19. This research has shown that the social blockade is very effective in controlling the spread of disease.
For COVID-19, there is no specific vaccines or antiviral drugs to treatment the disease and it is hard to control the spread of the disease. The best way to control the spread of COVID-19 is social blockade. However, the social blockade will have a serious impact on economic development and the normal lives of the people. Therefore, in order not to affect the normal life of non-infected persons, we proposed the strategy of isolating infected people to study the spread of the disease. Nowadays, there is a kind of infectious patients who have no symptoms, disseminating the infection disease and causing social panic. In 2013, Ma et al. [16] established an SEIIaHR epidemic model to study the spread of HFMD. The SEIIaHR isolates the infected person for treatment, while considering the role of recessive infection in the spread of HFMD. This is the same as our strategy in studying the spread of COVID-19. Therefore, we use the SEIIaHR model to study the impact of asymptomatic patients on the disease.
This paper is organized as follows: in the next section, we give the SEIIaHR model and describe the each symbol of the system. In section 3, we study the stability analysis of disease-free equilibrium and the persistence of the endemic equilibrium. Next, we take some numerical simulations for the system of (2.1) in section 4. Finally, we give some conclusions about COVID-19.
2.
Mathematical model
From the above discussions, we consider an SEIIaHR model with asymptomatic infected and quarantined on the symptomatic infected as following system
Here S(t),E(t),I(t),Ia(t),H(t),R(t) represent the numbers of the susceptible, exposed, symptomatic infected, asymptomatic infected, quarantined, recovered population at time t, respectively. Λ>0 describes the annual birth rate, β1,β2 are infection rates, 1σ represents the mean incubation period; p is the fraction of developing infectious cases, and the remaining fraction 1−p return to the recessive class; δ1 and δ2 are the disease-induced mortality for the infective and quarantined individuals, respectively; k is the quarantine rate; infective, quarantined and recessive individuals recover at the rate γ1, γ2 and γ3, respectively; d is the human natural mortality rate.
3.
Stability analysis
Define N(t)=S(t)+E(t)+I(t)+Ia(t)+H(t)+R(t), from system (2.1), we know that
dNdt≤Λ−dN,
it implies that the solutions of system (2.1) are bounded and the region
X={(S,E,I,Ia,H,R)∈R6+:S+E+I+Ia+H+R≤Λd}
(3.1)
is positively invariant for system (2.1). It is easy to see that system (2.1) has a disease-free equilibrium E0=(Λd,0,0,0,0,0). Using the next generation matrix formulated in Diekmam et al. [25] and van den Driessche and Watmough [26], we define the basic reproduction number by
R0=β1ΛσpdM1M2+β2Λσ(1−p)dM1M3,
(3.2)
here we denote M1=σ+d,M2=γ1+k+δ1+d,M3=γ3+d and M4=γ2+δ2+d. Thus we have the following theorem.
Theorem 3.1.If R0<1, then the disease-free equilibrium E0=(Λd,0,0,0,0) of the system (2.1) is global asymptotically stable.
Proof. we prove the global stability of the disease-free equilibrium. Define the Lypunov function as V(E,I,Ia)=β1M1M3I+β2M1M2Ia+(β1σpM3+β2σ(1−p)M2)E. For all t>0, the derivative of V(t) is
Here the relation S≤Λd has been utilized. If R0<1, we know that dVdt≤0, and dVdt=0 holds if and only if S=Λd, I=Ia=H=R=0. Using the LaSalle's extension to Lyapunov's method, the limit set of each solution is contained in the largest invariant set in {(S,E,I,Ia,H,R)∈X|dVdt=0} is the singleton {E0}. This means that the disease-free equilibrium E0 is globally asymptotically stable in X when R0<1.
Theorem 3.2.If R0>1, then the disease is uniformly persistent, i.e., there is a constant ε>0 such that every positive solution of system (2.1) satisfies
limt→∞I(t)≥ε,limt→∞Ia(t)≥ε.
(3.4)
Proof. Define
∂X={x(t)∈X:E(t)=0},X0=X−∂X.
In order to prove that the disease is uniformly persistent, we only need to show that ∂X repels uniformly the solutions of system (2.1) in X0. It is easy to verify that ∂X is relatively closed in X and is point dissipative. Let
X∂={x(t):x(t)∈∂X,∀t>0}.
(3.5)
We now show that X∂={(S1,0,0,0,0,0):0<S1≤Λd}. Assume that x(t)∈X∂ for all t≥0, then we have E(t)=0 for all t≥0. Thus, by the second equation of system (2.1), we have S(t)[β1I1(t)+β2Ia(t)]=0, which implies that I(t)=0,Ia(t)=0 for all t≥0. Indeed, if I(t)≠0,Ia(t)≠0, there is a t0≥0 such that I(t0)>0,Ia(t)>0, form the second equation of system (2.1), we have
dEdt|t=t0=β1SI(t0)+β2SIa(t0)>0.
(3.6)
It exists a t1>t0 such that E(t1)>0,dIdt|t1=σpE(t1)>0,dIadt|t1=σ(1−p)E(t1)>0, it follows that there is a η>0 such that I(t),Ia(t)>0 for t1<t<t1+η. This means that x(t)∉X∂ for t1<t<t1+η, which contradicts to the assume x(t)∈X∂ for all t≥0. Therefore, X∂={(S1,0,0,0,0,0):0<S1≤Λd}.
By analyzing system (2.1), it is clear that E0 is unique equilibrium in ∂X. Next, we will show that E0 repels the solutions of system (2.1) in X0. We analyze the behavior of any solution x(t) of system (2.1) close to E0. We divide the initial data into two cases.
● If E(0)=I(0)=Ia(0)=0, then E(t)=I(t)=Ia(t)=0. System (2.1) implies that S(t) goes away from E0 as t→−∞.
● If E(0),I(0),Ia(0)>0, then E(t),I(t),Ia(t)≥0 for all t>0. When x(t) stays close to E0, by the system (2.1) there exists a ρ small enough such that
where ˜a11=−(d+σ)−ρ, ˜a12=Λβ1d−ρ, ˜a13=Λβ2d−ρ, ˜a21=σp, ˜a22=−M2, ˜a31=σ1(1−p),˜a33=−(d+γ3), and largest eigenvalue of the coefficient matrix ˜A(˜aij) of the right hand of (3.7) is positive, since R0>1[25]. Hence the solutions of the linear quasi-monotonic system
with y1(0),ya(0)>0 are increasing as t→∞. By the comparison principle, (E,I1,Ia) goes away from (0,0,0,0,0). Therefore, {E0} is an isolated invariant set and acyclic. Using Theorem 4.3 in Freedman [27], system (2.1) is uniformly persistent. Thus, the proof of Theorem 3.2 is completed.
Biologically speaking, Theorem 3.2 shows that the disease is uniformly persistent if R0>1, and all the solutions of system are ultimately bounded in X, then system has at least one positive solution By Zhao [28]. Therefore, we have the following theorem.
Theorem 3.3.If R0>1, then the system (2.1) has an endemic equilibrium E⋆=(S∗,E∗,I∗,I∗a,H∗,R∗).
Proof. From the third and forth equations of system (2.1), we can conclude that
where M1,M2,M3 and M4 are mentioned in (3.2). Substituting S∗, I∗ and I∗a in the second equation of (2.1) at steady state, we obtain the following equation
E∗=M2M3dβ1M3σp+β2M2σ(1−p)(R0−1).
(3.8)
Here we should show the term S∗ is positive, from the above Eq (3.8), we have S∗=M1M2M3β1M3σp+β2M2σ(1−p)>0. From the similar argument, we have I∗,I∗a,H∗,R∗>0, i.e., the system has at most one positive solution. Therefore, if R0>1, the system has an endemic equilibrium.
4.
Simulations and results
Since the first case was reported to WHO on 31st December 2019, the COVID-19 has spread rapidly worldwide. As of December 21, 2020 there are 220 countries were infected, and there are many countries still trap in the epidemic. In this section, we consider the study of spread of COVID-19 disease in India. India is observing an increase in the number of patients each day. The accuracy of our proposed model is validated by using the official data of India from[29,30,31].
The study consider currently infected patients of India from May 1st 2020 to November 15th 2020. The population of India is around N=1386750000[29], thus we assumed that the initial value is S(0)=N−E(0)−Ia(0)−I(0)−H(0)−R(0), E(0)=315236, Ia=78809, I(0)=236427, H(0)=7880, R(0)=59646. Then we illustrate the source of parameters in following. We can get the value of population input into the susceptible class through birth 77575 per day in India, and the average life expectancy of India is 70.42. Noting that 1/d is the average life expectancy, the value of parameter d can be calculated as d=1/(70.42×365)=3.8904×10−5. We choose the 1/σ=2.5 which represent the average period of from the susceptible to the exposed. Because the average recovered period of the quarantined about is 14 days, so we choose the parameter γ2=1/14=0.0714. The parameters of system (2.1) are listed in Table 1.
We use the Markov Chain Monte Carlo (MCMC) method to fit the parameters β1, β2 to the data, and adopt an adaptive Metropolis-Hastings (M-H) algorithm to carry out the MCMC procedure. The algorithm is run for 10,000 iterations with a burn-in of the first 6,000 iterations, and the Geweke convergence diagnostic method is employed to assess convergence of chains. In Figure 1, we have plotted the curves between the total number of COVID-19 cases versus days (till November 15, 2020) in India based on the actual data and the proposed model (2.1). The estimation results some parameters are given in Table 2 and Figure 2.
Figure 1.
COVID spread in India and simulated by MCMC(Days from May 1st 2020).
For the quarantine rate k, we have chosen two different values as a comparison to show the importance of quarantine measures for symptomatic infected to control the spread of disease. Figure 3 shows the relationship between quarantine rate k and basic reproduction number R0. We can see that R0 and k are negatively correlated. After calculation, we get the critical point kc=0.4949, then we have R0 is equal to 1. Figure 4 is the evolution of system (2.1) when k=0.8, 0.01, respectively. If k=0.8, we compute the basic reproduction number R0=0.7741<1, it can be seen that the disease-free equilibrium E0 is globally asymptotically stable (see Figure 4a). If k=0.01, we calculate the basic reproduction number R0=2.1321>1, it can be seen that system (2.1) has a positive equilibrium point and it is is uniformly persistent (see Figure 4b).
Figure 3.
The relationship between quarantine rate k and R0.
Next, the impact of the treatment period(1/γ2) for quarantined on COVID-19 is analyzed. Figures 5 and 6 show the number of infected (I+Ia+H), quarantined (H), and cumulative deaths (COVID-19 deaths, excluding natural deaths) in different treatment period for R0<1 and R0>1 respectively. When R0<1, the shorter the treatment period, the disease will die out faster, and the fewer people will be isolated. At the same time, the cumulative number of deaths will be lower. When R0>1, the longer the treatment period, the more people will be infected and quarantined. Assuming that there are no individual differences, the treatment period is negatively related to the medical level. That is, the higher the medical level, the shorter the treatment period. This means that improving the level of medical treatment is conductive to the control of COVID-19. Therefore, it is urgent for India and other countries to develop specific drugs against COVID-19.
Figure 5.
The impact of the treatment period for quarantined on COVID-19: k=0.8,R0=0.7741<1.
Then, we show the relationship between parameters k,β2 and R0. From Figure 7a, we know that the parameters k and R0 are negatively correlated, and the parameters β2 and R0 are positively correlated. When β2=2.0×10−11, the quarantine rate k has the maximum threshold k=0.5411>kc. When β2=0, the quarantine rate k has the minimum threshold k=0.3519<kc. Figure 7b, 7c show the relationship between β2 and R0 when k=0.01,0.8, respectively. When k=0.01, the disease is uniformly persistent, even the the parameter β2=0. If we select k=0.8, only when β2>3.6639×10−11 can affect the spread of the disease. Therefore, we deduce that when k>0.5411, asymptomatic infections do not affect the spread of the disease; when 0.3519<k<0.5411, it is related to the infection rate of asymptomatic people whether the disease persists. In general, the higher the quarantine rate of people with symptoms, the easier it is to control the spread of the disease.
Figure 7.
The relationship between parameters k,β2 and R0.
In this paper, we consider an SEIIaHR epidemic model with asymptomatic infection and isolation. First, We have proved that the disease-free equilibrium E0 is globally asymptotically stable if and only if R0<1 and the system (2.1) is uniformly persistent if R0>1. Our numerical simulation results are consistent with theoretical analysis. Second, we showed the impact of the treatment period(1/γ2) for quarantined on COVID-19. The better the medical treatment, the COVID-19 is more likely to die out or be controlled at a lower level. Therefore, it is urgent for India and other countries around the world to develop specific drugs against COVID-19. Third, we deduced that the parameters k and R0 are negatively correlated, and the parameters β2 and R0 are positively correlated. At the same time, we found that asymptomatic infections will affect the spread of the disease when the quarantine rate is within the range of [0.3519,0.5411] and isolating people with symptoms is very important to control and eliminate the disease in India and other countries.
Acknowledgments
The authors would like to thank the referees for helpful comments which resulted in much improvement of the paper. Project Supported by National Nature Science Foundation of China (Grant No. 12071445, 12001501), Fund for Shanxi 1331KIRT, Shanxi Natural Science Foundation (Grant No. 201901D211216) and the outstanding youth fund of North University of China.
Conflict of interest
The authors declare that they have no conflict of interest.
References
[1]
Charbord P (2010) Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther 21: 1045-1056. doi: 10.1089/hum.2010.115
Shi C, Zhu Y, Su Y, et al. (2006) Stem cells and their applications in skin-cell therapy. Trends Biotechnol 24: 48-52. doi: 10.1016/j.tibtech.2005.11.003
[4]
Sousa BR, Parreira RC, Fonseca EA, et al. (2014) Human adult stem cells from deverse origins: An overview from multiparametric immunophenotyping to clinical applications. Cytometry A 85: 43-77. doi: 10.1002/cyto.a.22402
[5]
Ullah I, Subbarao RB, Rho GJ (2015) Human mesenchymal stem cells – current trends and future prospective. Biosci Rep 35: e00191.
Chamberlain G, Fox J, Ashton B, et al. (2007) Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem cells 25: 2739-2749. doi: 10.1634/stemcells.2007-0197
[8]
Caplan AI (1991) Mesenchymal stem cells. J Orthop Res 9: 641-650. doi: 10.1002/jor.1100090504
[9]
Pittenger MF, Mackay AM, Beck SC, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147. doi: 10.1126/science.284.5411.143
[10]
Wegmeyer H, Bröske A-M, Leddin M, et al. (2013) Mesenchymal stromal cell characteristics vary depending on their origin. Stem Cells Dev 22: 2606-2618. doi: 10.1089/scd.2013.0016
[11]
Zouboulis CC, Adjaye J, Akamatsu H, et al. (2008) Human skin stem cells and the aging process. Experimental Gerontol 43: 986-997. doi: 10.1016/j.exger.2008.09.001
[12]
Fraser JK, Wulur I, Alfonso Z, et al. (2006) Fat tissue: An underappreciated source of stem cells for biotechnology. Trends Biotechnol 24: 150-154. doi: 10.1016/j.tibtech.2006.01.010
[13]
Zuk PA, Zhu M, Mizuno H, et al. (2001) Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 7: 211-228. doi: 10.1089/107632701300062859
[14]
Dominici M, Le Blanc K, Mueller I, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cryotherapy 8: 315-317.
[15]
Barry FP, Murphy JM, English K, et al. (2005) Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev 14: 252-265. doi: 10.1089/scd.2005.14.252
[16]
Caplan AI, Correa D (2011) The MSC: An injury drugstore. Cell Stem Cell 9: 11-15. doi: 10.1016/j.stem.2011.06.008
[17]
Chen L, Tredget EE, Wu PY, et al. (2008) Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS ONE 3: e1886. doi: 10.1371/journal.pone.0001886
[18]
Wang J, Liao L, Tan J (2011) Mesenchymal-stem-cell-based experimental and clinical trials: current status and open questions. Expert Opin. Biol Ther 11: 893-909. doi: 10.1517/14712598.2011.574119
[19]
Hoogduijn MJ (2015) Are mesenchymal stromal cells immune cells? Arthritis Res Ther 17: 88. doi: 10.1186/s13075-015-0596-3
[20]
Nauta AJ, Kruisselbrink AB, Lurvink E, et al. (2006) Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 177: 2080-2087. doi: 10.4049/jimmunol.177.4.2080
[21]
Bartholomew A, Sturgeon C, Siatskas M, et al. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30: 42-48. doi: 10.1016/S0301-472X(01)00769-X
[22]
McIntosh K, Zvonic S, Garrett S, et al. (2006) The immunogenicity of human adipose-derived cells: temporal changes in vitro. Stem Cells 24: 1246-1253. doi: 10.1634/stemcells.2005-0235
[23]
Lombardo E, DelaRosa O, Mancheño-Corvo P, et al. (2009) Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. Tissue Eng Part A 15: 1579-1589. doi: 10.1089/ten.tea.2008.0340
[24]
Puissant B, Barreau C, Bourin P, et al. (2005) Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 129: 118-129. doi: 10.1111/j.1365-2141.2005.05409.x
[25]
Gonzalez MA, Gonzalez-Rey E, Rico L, et al. (2009) Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 60: 1006-1019. doi: 10.1002/art.24405
[26]
Fang B, Song Y, Liao L, et al. (2007) Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 39: 3358-3362. doi: 10.1016/j.transproceed.2007.08.103
[27]
Cho KS, Roh HJ (2010) Immunomodulatory effects of adipose-derived stem cells in airway allergic diseases. Curr Stem Cell Res Ther 5: 111-115. doi: 10.2174/157488810791268681
[28]
Badillo AT, Redden RA, Zhang L, et al. (2007) Treatment of diabetic wounds with fetal murine mesenchymal stromal cells enhances wound closure. Cell Tissue Res 329: 301-311. doi: 10.1007/s00441-007-0417-3
[29]
Li H, Fu X, Ouyang Y, et al. (2006) Adult bone-marrow-derived mesenchymal stem cells contribute to wound healing of skin appendages. Cell Tissue Res 326: 725-736. doi: 10.1007/s00441-006-0270-9
[30]
Ma K, Liao S, He L, et al. (2011) Effects of nanofiber/stem cell composite on wound healing in acute full-thickness skin wounds. Tissue Eng Part A 17: 1413-1424. doi: 10.1089/ten.tea.2010.0373
[31]
Schneider RK, Pullen A, Kramann R, et al. (2010) Long-term survival and characterisation of human umbilical cord-derived mesenchymal stem cells on dermal equivalents. Differentiation 79: 182-193. doi: 10.1016/j.diff.2010.01.005
[32]
Wu Y, Chen L, Scott PG, et al. (2007) Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25: 2648-2659. doi: 10.1634/stemcells.2007-0226
[33]
Kwon DS, Gao X, Liu YB, et al. (2008) Treatment with bone-marrow derived stromal cells accelerates wound healing in diabetic rats. Int Wound J 5: 453-463. doi: 10.1111/j.1742-481X.2007.00408.x
[34]
Yoshikawa T, Mitsuno H, Nonaka I, et al. (2008) Wound therapy by marrow mesenchymal cell transplantation. Plast Reconstr Surg 121: 860-877. doi: 10.1097/01.prs.0000299922.96006.24
[35]
Falanga V, Iwamoto S, ChartierM, et al. (2007) Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 13: 1299-1312. doi: 10.1089/ten.2006.0278
[36]
Borue X, Lee S, Grove J, et al. (2004) Bone marrow-derived cells contribute to epithelial engraftment during wound healing. Am J Pathol 165: 1767-1772. doi: 10.1016/S0002-9440(10)63431-1
[37]
Sasaki M, Abe R, Fujita Y, et al. (2008) Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. J Immunol 180: 2581-2587. doi: 10.4049/jimmunol.180.4.2581
[38]
Shokrgozar MA, Fattahi M, Bonakdar S, et al. (2012) Healing potential of mesenchymal stem cells cultured on a collagen-based scaffold for skin regeneration. Iran Biomed J 16: 68-76.
[39]
Påunescu V, Deak E, Herman D, et al. (2007) In vitro differentiation of human mesenchymal stem cells to epithelial lineage. J Cell Mol Med 11: 502-508. doi: 10.1111/j.1582-4934.2007.00041.x
[40]
Hasegawa T, Sakamoto A, Wada A, et al. (2015) Keratinocyte progenitor cells reside in human subcutaneous adipose tissue. PLoS One 10: e0118402. doi: 10.1371/journal.pone.0118402
[41]
Chavez-Munoz C, Nguyen KT, Xu W, et al. (2013) Transdifferentiation of adipose-derived stem cells into keratinocyte-like cells: Engineering a stratified epidermis. PLoS One 8: e80587. doi: 10.1371/journal.pone.0080587
[42]
Dominici M, Le Blanc K, Mueller I, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
[43]
Kuroda Y, Kitada M, Wakao S, et al. (2010) Unique multipotent cells in adult human mesenchymal stem cell populations. Proc Natl Acad Sci USA 107: 8639-8643. doi: 10.1073/pnas.0911647107
[44]
Tsuchiyama K, Wakao S, Kuroda Y, et al. (2013) Functional melanocytes are readily reprogrammable from multilineage-differentiating stress-enduring (muse) cells, distinct stem cells in human fibroblasts. J Invest Dermatol 133: 2425-2435. doi: 10.1038/jid.2013.172
[45]
Squillaro T, Peluso G, Galderisi U (2016) Clinical Trials With Mesenchymal Stem Cells: an update. Cell Transplant 25: 829-848. doi: 10.3727/096368915X689622
[46]
Oraee-Yazdani S, Hafizi M, Atashi A, et al (2016) Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome. Spinal Cord 54: 102-109. doi: 10.1038/sc.2015.142
[47]
Le Blanc K, Rasmusson I, Sundberg B, et al. (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymalstem cells. Lancet 363: 1439-1441. doi: 10.1016/S0140-6736(04)16104-7
[48]
Ball LM, Bernardo ME, Roelofs H, et al. (2013) Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graftversus- host disease. Br J Haematol 163: 501-509. doi: 10.1111/bjh.12545
[49]
Kurtzberg J, Prockop S, Teira P, et al. (2014) Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant 20: 229-235. doi: 10.1016/j.bbmt.2013.11.001
[50]
Introna M, Lucchini G, Dander E, et al. (2014) Treatment of graft versus host disease with mesenchymal stromal cells: A phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant 20: 375-381. doi: 10.1016/j.bbmt.2013.11.033
[51]
Ringd´en O, Erkers T, Nava S, et al. (2013) Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. Stem Cells 31: 592-601. doi: 10.1002/stem.1314
[52]
Cotsarelis G (2006) Epithelial stem cells: a folliculocentric view. J Invest Dermatol 126: 1459-1468. doi: 10.1038/sj.jid.5700376
[53]
Ohyama M, Kobayashi T (2012) Isolation and characterization of stem cell-enriched human and canine hair follicle keratinocytes. Methods Mol Biol 879: 389-401. doi: 10.1007/978-1-61779-815-3_24
[54]
Staricco RG, Miller-Milinska A (1962) Activation of the amelanotic melanocytes in the outer root sheath of the hair follicle following ultra violet rays exposure. J Invest Dermatol 39: 163-164. doi: 10.1038/jid.1962.97
[55]
Quevedo WC Jr, Isherwoob JE (1961) Influence of hair growth cycle on melanocyte activation in rabbit skin after a single application of methylcholanthrene. J Invest Dermatol 27: 93-101.
[56]
Yamada T, Hasegawa S, Inoue Y, et al. (2013) Wnt/β-catenin and kit signaling sequentially regulate melanocyte stem cell differentiation in UVB-induced epidermal pigmentation. J Invest Dermatol 133: 2753-2762. doi: 10.1038/jid.2013.235
[57]
Cichorek M,Wachulska M, Stasiewicz A, et al. (2013) Skin melanocytes: biology and development. Postepy Dermatol Allergol 30: 30-41.
[58]
Watt FM, Jensen KB (2009) Epidermal stem cell diversity and quiescence. EMBO Mol Med 1: 260-267. doi: 10.1002/emmm.200900033
[59]
Sieber-Blum M, Grim M, Hu YF, et al. (2004) Pluripotent neural crest stem cells in the adult hair follicle. Dev Dyn 231: 258-269. doi: 10.1002/dvdy.20129
[60]
Koga M, Tango T (1988) Clinical features and course of type A and type B vitiligo. Br J Dermatol 118: 223-228. doi: 10.1111/j.1365-2133.1988.tb01778.x
[61]
Njoo MD, Westerhof W, Bos JD, et al. (1999) The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. Arch Dermatol 135: 1514-1521.
[62]
Spencer GA (1951) Skin transplantation in extensive vitiligo. AMA Arch Derm Syphilol 64: 514-515.
[63]
Hasegawa T, Suga Y, Ikejima A, et al. (2007) Suction blister grafting with CO2 laser resurfacing of the graft recipient site for vitiligo. J Dermatol 34: 490-492. doi: 10.1111/j.1346-8138.2007.00317.x
[64]
Falabella R (1983) Repigmentation of segmental vitiligo by autologous minigrafting. J Am Acad Dermatol 9: 514-521. doi: 10.1016/S0190-9622(83)70162-3
[65]
Yamauchi T, Yamasaki K, Tsuchiyama K, et al. (2017) A quantitative analysis of multilineaage-differentiating stress-enduring (Muse) cells in human adipose tissue and efficacy of melanocytes induction. J Dermatol Sci 86: 198-205. doi: 10.1016/j.jdermsci.2017.03.001
[66]
Yoo BY, Shin YH, Yoon HH, et al. (2010) Application of mesenchymal stem cells derived from bone marrow and umbilical cord in human hair multiplication. J Dermatol Sci 60:74-83. doi: 10.1016/j.jdermsci.2010.08.017
Randall VA (2001) Is alopecia areata an autoimmune disease? Lancet 358: 1922-1924. doi: 10.1016/S0140-6736(01)06943-4
[69]
Gilhar A, Landau M, Assy B, et al. (2001) Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdc(scid) mice. J Invest Dermatol 117: 1357-1362. doi: 10.1046/j.0022-202x.2001.01583.x
[70]
Byun JW, Kin HJ, Na K, et al. (2017) Bone marrow-derived mesenchymal stem cells prevent alopecia areata development through the inhibition of NKG2D expression: A pilot study. Exp Dermatol 25: 532-535.
[71]
Hilal L, Rochat A, Duquesnoy P, et al. (1993) A homozygous insertion-deletion in the type VII collagen gene (COL7A1) in Hallopeau-Siemens dystrophic epidermolysis bullosa. Nat Genet 5: 287-293. doi: 10.1038/ng1193-287
[72]
Fine JD, Eady RA, Bauer EA, et al. (2008) The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 58: 931-950. doi: 10.1016/j.jaad.2008.02.004
[73]
Freeman EB, Köglmeier J, Martinez AE, et al. (2008) Gastrointestinal complications of epidermolysis bullosa in children. Br J Dermatol 158: 1308-1314. doi: 10.1111/j.1365-2133.2008.08507.x
[74]
McGrath JA, Schofield OM, Ishida-Yamamoto A, et al. (1993) Cultured keratinocyte allografts and wound healing in severe recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 29: 407-419. doi: 10.1016/0190-9622(93)70203-6
[75]
Roseeuw D, De Raeve L, Dangoisse C, et al. (1994) Treatment of epidermolysis bullosa with human cultured epidermal allografts. Dermatology 189: 68-70. doi: 10.1159/000246998
[76]
Beele H, Naeyaert JM, Monstrey S, et al. (1995) Ulcers in pretibial epidermolysis bullosa. Grafting with autologous meshed split-thickness skin and allogeneic cultured keratinocytes. Arch Dermatol 131: 990-992.
[77]
Verplancke P, Beele H, Monstrey S, et al. (1997) Treatment of dystrophic epidermolysis bullosa with autologous meshed split-thickness skin grafts and allogeneic cultured keratinocytes. Dermatology 194: 380-382. doi: 10.1159/000246155
[78]
Eisenberg M, Llewelyn D (1998) Surgical management of hands in children with recessive dystrophic epidermolysis bullosa: use of allogeneic composite cultured skin grafts. Br J Plast Surg 51: 608-613. doi: 10.1054/bjps.1998.9997
[79]
Hasegawa T, Suga Y, Mizoguchi M, et al. (2004) Clinical trial of allogeneic cultured dermal substitute for the treatment of intractable skin ulcers in 3 patients with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 50: 803-804. doi: 10.1016/j.jaad.2003.08.013
[80]
Hasegawa T, Mizoguchi M, Haruna K, et al. (2007) Amnia for intractable skin ulcers with recessive dystrophic epidermolysis bullosa: Report of three cases. J Dermatol 34: 328-332. doi: 10.1111/j.1346-8138.2007.00281.x
[81]
Kiuru M, Itoh M, Cario MS, et al. (2010) Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa. Dermatol Clin 28: 371-382.
[82]
Wagner JE, Ishida-Yamamoto A, McGrath JA, et al. (2010) Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Eng J Med 363: 629-639. doi: 10.1056/NEJMoa0910501
[83]
Chino T, Tamai K, Yamazaki T, et al. (2008) Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance. Am J Pathol 173: 803-814. doi: 10.2353/ajpath.2008.070977
[84]
Conget P, Rodriguez F, Kramer S, et al. (2010) Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cryotherapy 12: 429-431.
[85]
Liao Y, Itoh M, Yang A, et al. (2014) Human cord blood-derived unrestricted somatic stem cells promote wound healing and have therapeutic potential for patients with recessive dystrophic epidermolysis bullosa. Cell Transplant 23: 303-317. doi: 10.3727/096368913X663569
[86]
Liao Y, Ivanova L, Zhu H, et al. (2015) Rescue of the mucocutaneous manifestations by human cord blood derived nonhematopoietic stem cells in a mouse model of recessive dystrophic epidermolysis bullosa. Stem Cells 33: 1807-1817. doi: 10.1002/stem.1966
[87]
Petrof G, Lwin SM, Martinez-Queipo M, et al. (2015) Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 135: 2319-2321. doi: 10.1038/jid.2015.158
[88]
Iinuma S, Aikawa E, Tamaki K, et al. (2015) Transplanted bone marrow-derived circulating PDGFRα+ cells restore type VII collagen in recessive dystrophic epidermolysis bullosa mouse skin graft. J Immunol 194: 1996-2003. doi: 10.4049/jimmunol.1400914
[89]
Woodley DT, Cogan J, Wang X, et al. (2014) De novo anti-type VII collagen antibodies in patients with recessive dystrophic epidermolysis bullosa. J Invest Dermatol 134: 1138-1140. doi: 10.1038/jid.2013.475
[90]
Bauer J, Schumann H, Sonnichsen K (2002) Molecular diagnostics facilitate distinction between lethal and non-lethal subtypes of junctional epidermolysis bullosa: a case report and review of the literature. Eur J Pediatr 161: 672-679. doi: 10.1007/s00431-001-0851-2
[91]
Yuen WY, Duipmans JC, Molenbuur B (2012) Long-term follow-up of patients with Herlitz-type junctional epidermolysis bullosa. Br J Dermatol 167: 374-382 doi: 10.1111/j.1365-2133.2012.10997.x
[92]
Mavilio F, Pellegrini G, Ferrari S, et al. (2006) Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermolysis bullosa by transplantaation of genetically modified epidermal stem cells. Nat Med 12: 1397-1342.
[93]
Osmanov T, Ugrinova I, Pasheva E (2013) The chaperone like function of the nonhistone protein HMGB1. Biochem Biophys Res Commun 432: 231-235. doi: 10.1016/j.bbrc.2013.02.008
[94]
Tang D, Shi Y, Kang R, et al. (2007) Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol 81: 741-747.
[95]
Dumitriu IE, Baruah P, Valentinis B, et al. (2005) Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174: 7506-7515. doi: 10.4049/jimmunol.174.12.7506
[96]
Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cell triggers inflammation. Nature 418: 191-195. doi: 10.1038/nature00858
[97]
Park JS, Gamboni-Robertson F, He Q, et al. (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290: C917-924.
[98]
Yanai H, Ban T, Taniguchi T (2012) High-mobility group box family of proteins: ligand and sensor for innate immunity. Trends Immunol 33: 633-640. doi: 10.1016/j.it.2012.10.005
[99]
Takahashi K, Fukushima S, Yamahara K, et al. (2008) Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart. Circulation 118: S106-114. doi: 10.1161/CIRCULATIONAHA.107.757443
[100]
Straino S, Di Cario A, Mangoni A, et al. (2008) High-mobility group box 1 protein in human and murine skin: involvement in wound healing. J Invest Dermatol 128: 1545-1553. doi: 10.1038/sj.jid.5701212
[101]
Palumbo R et al. (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 164: 441-449. doi: 10.1083/jcb.200304135
[102]
Clavakis E, Hain A, Vinci M, et al. (2007) High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res 100: 204-212. doi: 10.1161/01.RES.0000257774.55970.f4
[103]
Tamai K, Yamazaki T, Chino T, et al. (2011) PDGFRα-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia. Proc Natl Acad Sci USA 108: 6609-6614. doi: 10.1073/pnas.1016753108
[104]
Jeremias TS, Machado RG, Visoni SB, et al. (2014) Dermal substitutes support the growth of human skin-derived mesenchymal stromal cells. PLoS One 9: e89542. doi: 10.1371/journal.pone.0089542
This article has been cited by:
1.
Yifei Ma, Shujun Xu, Qi An, Mengxia Qin, Sitian Li, Kangkang Lu, Jiantao Li, Lijian Lei, Lu He, Hongmei Yu, Jun Xie,
Coronavirus disease 2019 epidemic prediction in Shanghai under the “dynamic zero-COVID policy” using time-dependent SEAIQR model,
2022,
4,
25889338,
105,
10.1016/j.jobb.2022.06.002
2.
R. Prem Kumar, Sanjoy Basu, P.K. Santra, D. Ghosh, G.S. Mahapatra,
Optimal control design incorporating vaccination and treatment on six compartment pandemic dynamical system,
2022,
7,
26667207,
100115,
10.1016/j.rico.2022.100115
3.
Rongping Zhang, Maoxing Liu, Boli Xie,
The analysis of discrete-time epidemic model on networks with protective measures on game theory,
2022,
158,
09600779,
112029,
10.1016/j.chaos.2022.112029
4.
Songbai Guo, Yuling Xue, Rong Yuan, Maoxing Liu,
An improved method of global dynamics: Analyzing the COVID-19 model with time delays and exposed infection,
2023,
33,
1054-1500,
10.1063/5.0144553
5.
江波 郝,
Dynamic Analysis of Epidemic Models with Self-Protection and Isolation Measures,
2023,
12,
2324-7991,
4998,
10.12677/AAM.2023.1212491
6.
Jiangbo Hao, Lirong Huang, Maoxing Liu, Yangjun Ma,
Analysis of the COVID-19 model with self-protection and isolation measures affected by the environment,
2024,
21,
1551-0018,
4835,
10.3934/mbe.2024213
7.
Erhui Li, Qingshan Zhang,
Global dynamics of an endemic disease model with vaccination: Analysis of the asymptomatic and symptomatic groups in complex networks,
2023,
31,
2688-1594,
6481,
10.3934/era.2023328
8.
Feng Chen, Jing Hu, Yuming Chen, Qimin Zhang,
Stability of a semi-Markovian hybrid switching system with application to an epidemic model,
2024,
0,
1531-3492,
0,
10.3934/dcdsb.2024185